PDE4 is considered a versatile pharmacological target, and its inhibitors are being explored for the treatment of cystic fibrosis, multiple sclerosis, CNS disorders such as depression, and cancer, where they modulate inflammation and immune responses [12,13,14]. The gene discussed is PDE4A; the disease is cancer.